Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant Advocacy Hub | UniteRare

At a Glance

Live from database

Regulatory Watchboard

3 events

Aug 2025Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant

Lexeo Therapeutics

TrialENROLLING BY INVITATION

Mar 2025Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

Hamilton Health Sciences Corporation — PHASE2

TrialRECRUITING

Feb 2024Gene Therapy for ACM Due to a PKP2 Pathogenic Variant

Lexeo Therapeutics — PHASE1, PHASE2

TrialACTIVE NOT RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant.
Check the disease page for updates →

Clinical Trial Landscape

3 active trials

1Phase 2

1Unknown

1PHASE1, PHASE2

3Total recruiting

Search clinical trials for Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant →

Recent News & Research

No recent news articles indexed yet for Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant.
Search PubMed for Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant →

Browse all Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant news →

Specialist Network

No specialists currently listed for Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant.

View all Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰